ECSS
SRPT icon

Eurizon Capital SGR SpA’s Sarepta Therapeutics SRPT Stock Holding History

Eurizon Capital SGR SpA’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.6K Hold
797
– – ﹤0.01% 1165
2026
Q1 		$16.4K Hold
797
– – ﹤0.01% 1108
2025
Q4 		$17.1K Buy
+797
New +$16.8K ﹤0.01% 978

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Eurizon Capital SGR SpA's SRPT Position: Q2 2026 in Review

Eurizon Capital SGR SpA held its Sarepta Therapeutics (SRPT) position steady in Q2 2026 at 797 shares worth $13.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1165.

Eurizon Capital SGR SpA first reported a position in SRPT in Q4 2025 and has held it in 3 quarters since. The position peaked at $17.1K in Q4 2025. 320 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Eurizon Capital SGR SpA held 797 shares of Sarepta Therapeutics worth $13.6K as of Q2 2026.
  • Eurizon Capital SGR SpA left its Sarepta Therapeutics share count unchanged in Q2 2026.
  • Sarepta Therapeutics made up ﹤0.01% of Eurizon Capital SGR SpA's portfolio in Q2 2026, its #1165 holding.
  • Eurizon Capital SGR SpA first reported a position in Sarepta Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Eurizon Capital SGR SpA's Sarepta Therapeutics position peaked at $17.1K in Q4 2025.
  • 320 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Eurizon Capital SGR SpA's 13F filing for Q2 2026, filed 29 Jul 2026.